A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...

Camrelizumab increased the 3-year event-free survival rate vs standard of care from 77.3% to 86.9%, translating to a 44% ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric ...

Arnab Basu, MD, MPH, FACP, discussed his research on high-sensitivity circulating tumor DNA assays in genitourinary ...

David Sallman, MD, discusses some of the innovative therapies and strategies being investigated in myelodysplastic syndromes studies.

With immunotherapy-based regimens and novel agents like bispecific antibodies and antibody-drug conjugates, oncologist David ...

In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...

GLP-1 agonists, widely used for obesity and diabetes management, have been associated with a reduced risk of most ...

Osimertinib is now an FDA-approved therapy for stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations that ...